Myeloma-Developing Regimens Using Genomics (MyDRUG)
Public ClinicalTrials.gov record NCT03732703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).
Study identification
- NCT ID
- NCT03732703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- Abemaciclib, dexamethasone, ixazomib, pomalidomide Drug
- Enasidenib, dexamethasone, ixazomib, pomalidomide Drug
- Cobimetinib, dexamethasone, ixazomib, pomalidomide Drug
- Erdafitinib, dexamethasone, ixazomib, pomalidomide Drug
- Venetoclax, dexamethasone, ixazomib, pomalidomide Drug
- Daratumumab, dexamethasone, ixazomib, pomalidomide Drug
- Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide Drug
- Selinexor, dexamethasone, ixazomib, pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2019
- Primary completion
- Dec 30, 2024
- Completion
- Dec 30, 2024
- Last update posted
- Feb 13, 2025
2019 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Arizona | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Minnesota | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine Division of Medical Oncology | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07610 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Ohio State University College of Medicine | Columbus | Ohio | 43210 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03732703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2025 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03732703 live on ClinicalTrials.gov.